Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) EBITDA (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed EBITDA for 5 consecutive years, with -$6.0 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA rose 49.5% to -$6.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$33.0 million, a 66.22% increase, with the full-year FY2024 number at -$93.5 million, down 49.17% from a year prior.
  • EBITDA was -$6.0 million for Q3 2025 at Lyra Therapeutics, up from -$7.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$6.0 million in Q3 2025 to a low of -$48.2 million in Q2 2024.
  • A 5-year average of -$14.6 million and a median of -$13.6 million in 2021 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: crashed 208.07% in 2024, then surged 84.56% in 2025.
  • Lyra Therapeutics' EBITDA stood at -$13.6 million in 2021, then dropped by 4.47% to -$14.2 million in 2022, then decreased by 6.26% to -$15.1 million in 2023, then increased by 27.24% to -$11.0 million in 2024, then soared by 45.6% to -$6.0 million in 2025.
  • Per Business Quant, the three most recent readings for LYRA's EBITDA are -$6.0 million (Q3 2025), -$7.4 million (Q2 2025), and -$8.5 million (Q1 2025).